We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-9.76%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$16.2B
AUM Growth
-$2.57B
Cap. Flow
+$150M
Cap. Flow %
0.93%
Top 10 Hldgs %
86.32%
Holding
116
New
17
Increased
25
Reduced
19
Closed
6

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$49.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$43.3M
3
KOD icon
Kodiak Sciences
KOD
+$31.6M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$27.5M
5
ALLK
Allakos
ALLK
+$27.1M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$60M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$48.2M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$10.4M
4
QURE icon
uniQure
QURE
+$9.23M
5
NXTC icon
NextCure
NXTC
+$8.45M

Sector Composition

Rank Sector Weight
1 Healthcare 98.58%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
51
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$8.08M 0.05%
55,983
+15,000
+37% +$2.9M
SYRE icon
52
Spyre Therapeutics
SYRE
$8.25B
$7.99M 0.05%
68,544
– –
IFRX icon
53
InflaRx
IFRX
$246M
$6.79M 0.04%
1,778,415
– –
ALEC icon
54
Alector
ALEC
$170M
$6.76M 0.04%
+280,000
New +$7.14M
SGMO
55
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.37M 0.04%
999,823
– –
BDSI
56
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$6.21M 0.04%
+1,638,334
New +$8.05M
FLGT icon
57
Fulgent Genetics
FLGT
$558M
$6.13M 0.04%
569,444
– –
ACGN
58
DELISTED
Aceragen Inc
ACGN
$6.08M 0.04%
271,376
– –
ALBO
59
DELISTED
Albireo Pharma Inc
ALBO
$6.04M 0.04%
369,047
+119,047
+48% +$2.62M
HZNP
60
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.92M 0.04%
+200,000
New +$6.77M
HOOK
61
DELISTED
HOOKIPA Pharma
HOOK
$5.78M 0.04%
70,048
-19,238
-22% -$2.11M
ISEE
62
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.63M 0.03%
1,635,501
+1,493,751
+1,054% +$8.73M
CABA icon
63
Cabaletta Bio
CABA
$429M
$4.64M 0.03%
636,363
– –
TARA icon
64
Protara Therapeutics
TARA
$213M
$4.59M 0.03%
+199,671
New +$5.82M
TPST icon
65
Tempest Therapeutics
TPST
$14M
$4.4M 0.03%
4,274
– –
PASG icon
66
Passage Bio
PASG
$14.2M
$4.33M 0.03%
+13,750
New +$4.3M
CNST
67
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$4.19M 0.03%
133,333
– –
IMMU
68
DELISTED
Immunomedics Inc
IMMU
$4.18M 0.03%
+310,000
New +$5.22M
NERV icon
69
Minerva Neurosciences
NERV
$192M
$4.14M 0.03%
+86,066
New +$5.19M
SYRS
70
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.09M 0.03%
69,017
– –
CPRX
71
DELISTED
Catalyst Pharmaceutical
CPRX
$4.08M 0.03%
1,060,714
-281,188
-21% -$1.15M
ABEO icon
72
Abeona Therapeutics
ABEO
$342M
$3.34M 0.02%
63,627
-27,902
-30% -$1.86M
ANAB icon
73
AnaptysBio
ANAB
$1.53B
$3.31M 0.02%
234,592
+121,506
+107% +$1.84M
EVFM
74
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$3.31M 0.02%
41,420
-9,034
-18% -$723K
MTEM
75
DELISTED
Molecular Templates, Inc.
MTEM
$3.16M 0.02%
15,861
-5,254
-25% -$1.15M
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Baker Bros. Advisors held 116 positions worth $16.2B, down 14% from $18.8B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q1 2020 filing shows 17 new, 25 increased, 19 reduced and 6 closed positions. Its largest new stake was Adaptimmune Therapeutics: 3,690,307 shares worth $10M. The largest sale was Exact Sciences, an estimated $60M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2020 buy was Adaptimmune Therapeutics: 3,690,307 shares worth $10M.
  • Baker Bros. Advisors added most to Alexion Pharmaceuticals in Q1 2020, an estimated $49.3M increase.
  • Baker Bros. Advisors's biggest Q1 2020 reduction was Exact Sciences, cutting an estimated $60M.
  • Baker Bros. Advisors fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $48.2M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $16.2B portfolio in Q1 2020.
  • Baker Bros. Advisors opened 17 new positions and closed 6 in Q1 2020.
  • Baker Bros. Advisors's portfolio value fell 14% quarter-over-quarter to $16.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2020, filed 15 May 2020.